Skip to content

Advertisement

  • Poster presentation
  • Open Access

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein

  • 1,
  • 1,
  • 1,
  • 1,
  • 1, 2,
  • 1 and
  • 1
Journal for ImmunoTherapy of Cancer20131(Suppl 1):P218

https://doi.org/10.1186/2051-1426-1-S1-P218

Published: 7 November 2013

Keywords

  • Native Peptide
  • Tumor Cell Target
  • Vector Vaccine
  • Vaccine Target
  • Agonist Peptide

Purpose

The MUC1 tumor-associated antigen is overexpressed in the majority of human carcinomas and several hematologic malignancies. Much attention has been paid to the hypoglycosylated VNTR region of the N-terminus of MUC1 as a vaccine target, and recombinant viral vector vaccines are also being evaluated that express the entire MUC1 transgene. While previous studies have described MUC1 as a tumor-associated tissue differentiation antigen, numerous studies have now determined that the C-terminus of MUC1 (MUC1-C) is an oncoprotein, and its expression is an indication of poor prognosis in numerous tumor types.

Experimental design

We report here the identification of seven potential CD8+ cytotoxic T lymphocyte epitopes of MUC1: five in the C-terminus and two in the VNTR region, and have identified enhancer agonist peptides for each of these epitopes. These epitopes span HLA-A2 and A3 MHC class I alleles, which encompass two thirds of the population.

Results

The agonist peptides, compared to the native peptides, more efficiently (a) generate T-cell lines from the peripheral blood mononuclear cells of cancer patients, (b) enhance the production of IFN-γ by peptide-activated human T cells, and (c) lyse human tumor cell targets in an MHC-restricted manner.

Conclusions

The agonist epitopes described here can be incorporated in various vaccine platforms and for ex vivo generation of human T cells. These studies thus provide the rationale for the T-cell-mediated targeting of the oncogenic C-terminus of MUC1, which has been shown to be an important factor in both drug resistance and poor prognosis for numerous tumor types.

Authors’ Affiliations

(1)
Laboratory of Tumor Immunology and Biology, NCI, Bethesda, USA
(2)
Medical Oncology Branch, NCI, Bethesda, USA

Copyright

© Jochems et al; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement